Search Results - "Widemann, B."

Spatially explicit regionalization of airborne flux measurements using environmental response functions by Metzger, S, Junkermann, W, Mauder, M, Butterbach-Bahl, K, Trancón y Widemann, B, Neidl, F, Schäfer, K, Wieneke, S, Zheng, X. H, Schmid, H. P, Foken, T

“…The goal of this study is to characterize the sensible (H) and latent (LE) heat exchange for different land covers in the heterogeneous steppe landscape of the…”
Get full text

The primacy of NF1 loss as the driver of tumorigenesis in neurofibromatosis type 1-associated plexiform neurofibromas by Pemov, A, Li, H, Patidar, R, Hansen, N F, Sindiri, S, Hartley, S W, Wei, J S, Elkahloun, A, Chandrasekharappa, S C, Boland, J F, Bass, S, Mullikin, J C, Khan, J, Widemann, B C, Wallace, M R, Stewart, D R

“…Neurofibromatosis type 1 (NF1) is a common tumor-predisposition disorder due to germline mutations in the tumor suppressor gene NF1 . A virtually pathognomonic…”
Get full text

Characteristics of children enrolled in treatment trials for NF1-related plexiform neurofibromas by KIM, A, GILLESPIE, A, DOMBI, E, GOODWIN, A, GOODSPEED, W, FOX, E, BALIS, F. M, WIDEMANN, B. C

“…To describe the characteristics of children enrolled in treatment trials for neurofibromatosis type 1 (NF1)-related plexiform neurofibroma (PN), PN tumor…”
Get full text

Vandetanib Successfully Controls Medullary Thyroid Cancer-Related Cushing Syndrome in an Adolescent Patient by Nella, A. A, Lodish, M. B, Fox, E, Balis, F. M, Quezado, M. M, Whitcomb, P. O, Derdak, J, Kebebew, E, Widemann, B. C, Stratakis, C. A

“…Context: Ectopic Cushing syndrome due to ACTH secretion from metastatic medullary thyroid cancer (MTC) is associated with significant morbidity and mortality…”
Get full text

Algebraic–coalgebraic recursion theory of history-dependent dynamical system models by Trancón y Widemann, B., Hauhs, M.

“…We investigate the common recursive structure of history-dependent dynamic models in science and engineering. We give formal semantics in terms of a hybrid…”
Get full text

NF1 plexiform neurofibroma growth rate by volumetric MRI: relationship to age and body weight by Dombi, E, Solomon, J, Gillespie, A J, Fox, E, Balis, F M, Patronas, N, Korf, B R, Babovic-Vuksanovic, D, Packer, R J, Belasco, J, Goldman, S, Jakacki, R, Kieran, M, Steinberg, S M, Widemann, B C

“…To longitudinally analyze changes in plexiform neurofibroma (PN) volume in relation to age and body growth in children and young adults with neurofibromatosis…”
Get full text

Phase I trial of pegylated interferon-alpha-2b in young patients with plexiform neurofibromas by Jakacki, R I, Dombi, E, Potter, D M, Goldman, S, Allen, J C, Pollack, I F, Widemann, B C

“…Interferon has antiproliferative and antiangiogenic properties. We sought to evaluate preliminary efficacy and determine the recommended phase II dose (RP2D)…”
Get full text

Phase I trial of pegylated interferon-α-2b in young patients with plexiform neurofibromas by JAKACKI, R. I, DOMBI, E, POTTER, D. M, GOLDMAN, S, ALLEN, J. C, POLLACK, I. F, WIDEMANN, B. C

Get full text

Sirolimus for progressive neurofibromatosis type 1-associated plexiform neurofibromas: a neurofibromatosis Clinical Trials Consortium phase II study by Weiss, Brian, Widemann, Brigitte C, Wolters, Pamela, Dombi, Eva, Vinks, Alexander, Cantor, Alan, Perentesis, John, Schorry, Elizabeth, Ullrich, Nicole, Gutmann, David H, Tonsgard, James, Viskochil, David, Korf, Bruce, Packer, Roger J, Fisher, Michael J

“…Plexiform neurofibromas (PNs) are benign peripheral nerve sheath tumors that arise in one-third of individuals with neurofibromatosis type 1 (NF1). They may…”
Get full text

Radiation Therapy in Management of Sporadic and Neurofibromatosis Type 1 (NF1) Associated Malignant Peripheral Nerve Sheath Tumors (MPNST) by Kahn, J, Gillespie, A, Ondos, J, Dombi, E, Camphausen, K, Widemann, B, Kaushal, A

Get full text

Phase II trial of intravenous lobradimil and carboplatin in childhood brain tumors : a report from the Children's Oncology Group by WARREN, K, JAKACKI, R, OSBORNE, C, CEHELSKY, J, CALDWELL, D, STANWOOD, J, STEINBERG, S. M, BALIS, F. M, WIDEMANN, B, AIKIN, A, LIBUCHA, M, PACKER, R, VEZINA, G, REAMAN, G, SHAW, D, KRAILO, M

“…[corrected] Lobradimil is a synthetic bradykinin analog that rapidly and transiently increases the permeability of the blood-brain barrier (BBB). The…”
Get full text

Clinical Drug Development for Childhood Cancers by Balis, FM, Fox, E, Widemann, BC, Adamson, PC

Get full text

Pediatric phase I trial and pharmacokinetic study of the platelet-derived growth factor (PDGF) receptor pathway inhibitor SU101 by ADAMSON, P. C, BLANEY, S. M, BALIS, F. M, WIDEMANN, B. C, KITCHEN, B, MURPHY, R. F, HANNAH, A. L, CROPP, G. F, PATEL, M, GILLESPIE, A. F, WHITCOMB, P. G

“…To determine the maximum tolerated dose and the toxicity profile of the PDGF receptor pathway inhibitor SU101 in pediatric patients with refractory solid…”
Get full text

Carboxypeptidase-G2, thymidine, and leucovorin rescue in cancer patients with methotrexate-induced renal dysfunction by Widemann, B C, Balis, F M, Murphy, R F, Sorensen, J M, Montello, M J, O'Brien, M, Adamson, P C

“…Methotrexate nephrotoxicity can lead to delayed methotrexate elimination and the development of life-threatening toxicity, which may not be preventable with…”
Get more information

Pharmacokinetics and metabolism of the methotrexate metabolite 2, 4-diamino-N(10)-methylpteroic acid by Widemann, B C, Sung, E, Anderson, L, Salzer, W L, Balis, F M, Monitjo, K S, McCully, C, Hawkins, M, Adamson, P C

“…The novel methotrexate (MTX) rescue agent carboxypeptidase-G(2) (CPDG(2)) converts >98% of plasma MTX to 2, 4-diamino-N(10)-methylpteroic acid (DAMPA) and…”
Get more information

Dihydrofolate Reductase Enzyme Inhibition Assay for Plasma Methotrexate Determination Using a 96-Well Microplate Reader by Widemann, Brigitte C, Balis, Frank M, Adamson, Peter C

“…Microplate reader assays offer several advantages over conventional spectrophotometric assays. We adapted the dihydrofolate reductase (DHFR) enzyme inhibition…”
Get full text

Meeting report: pharmacology in pediatric oncology. Summary of the 10th international expert meeting of the Kind Philipp Foundation for leukemia research, June 10 - 13, 2001 at the Schloss Reisensburg, Günzburg an der donau by Widemann, B C, Boos, J

“…The Kind-Philipp foundation invited a group of international experts from academia, industry, and regulatory institutions to discuss aspects of new drug…”
Get more information

Carboxypeptidase-G2 rescue in a patient with high dose methotrexate-induced nephrotoxicity by Widemann, B C, Hetherington, M L, Murphy, R F, Balis, F M, Adamson, P C

“…High dose methotrexate (HDMTX) induced renal failure is a medical emergency, as methotrexate (MTX) is primarily eliminated by renal excretion. High doses of…”
Get more information

Plasma pharmacokinetics and cerebrospinal fluid penetration of thioguanine in children with acute lymphoblastic leukemia : a collaborative Pediatric Oncology Branch, NCI, and Children's Cancer Group study by LOWE, Elizabeth S, KITCHEN, Brenda J, WIDEMANN, Brigitte C, BALIS, Frank M, MURPHY, Robert F, ADAMSON, Peter C, ERDMANN, Gary, STORK, Linda C, BOSTROM, Bruce C, HUTCHINSON, Ray, HOLCENBERG, John, REAMAN, Gregory H, WOODS, William, FRANKLIN, Janet

“…In preclinical studies, thioguanine (TG) has been shown to be more potent than the standard acute lymphoblastic leukemia (ALL) maintenance agent,…”
Get full text

The plasma pharmacokinetics and cerebrospinal fluid penetration of the thymidylate synthase inhibitor raltitrexed (Tomudex) in a nonhuman primate model by WIDEMANN, B. C, BALIS, F. M, GODWIN, K. S, MCCULLY, C, ADAMSON, P. C

“…Raltitrexed (Tomudex), ZD1694) is a novel quinazoline folate analog that selectively inhibits thymidylate synthase. Intracellularly, raltitrexed is…”
Get full text